We are live on ! Find out more
CANF

Can-Fite BioPharma American Depositary Shares
CANF

15 hedge funds and large institutions have $626K invested in Can-Fite BioPharma American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

25% more funds holding

Funds holding: 12 → 15 (+3)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

74% less capital invested

Capital invested by funds: $2.43M → $626K (-$1.8M)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$57.6K
2
TSS
Two Sigma Securities
New York
+$24.5K
3
HF
HRT Financial
New York
+$16.5K
4
Bank of America
Bank of America
North Carolina
+$551

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.45M
2
Renaissance Technologies
Renaissance Technologies
New York
-$155K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$119K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$308K +$57.6K +209 +21%
CAN
2
Cetera Advisor Networks
California
$169K – – –
Fifth Third Bancorp
3
Fifth Third Bancorp
Ohio
$39K – – –
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$36K -$119K -431 -75%
TSS
5
Two Sigma Securities
New York
$23K +$24.5K +89 New
Stifel Financial
6
Stifel Financial
Missouri
$15K – – –
HF
7
HRT Financial
New York
$15K +$16.5K +60 New
National Bank of Canada
8
National Bank of Canada
Quebec, Canada
$8K +$8.26K +30 New
Citigroup
9
Citigroup
New York
$7K – – –
Wells Fargo
10
Wells Fargo
California
$2K – – –
APA
11
American Portfolios Advisors
New York
$1.42K – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$1K – – –
Bank of America
13
Bank of America
North Carolina
$1K +$551 +2 New
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$688 – – –
TWC
15
TD Waterhouse Canada
Ontario, Canada
$354 +$275 +1 New
AC
16
Armistice Capital
New York
– -$1.45M -4,375 Closed
Renaissance Technologies
17
Renaissance Technologies
New York
– -$155K -467 Closed

CANF Hedge Fund Activity: Q4 2021 in Review

15 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2021, worth a combined $626K — down 74% from $2.43M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CANF positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $57.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.45M sold.

  • 15 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2021, up from 12 in Q3 2021.
  • Funds reported $626K of Can-Fite BioPharma American Depositary Shares stock for Q4 2021, down 74% quarter-over-quarter.
  • 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2021 and 2 closed out, a net change of +3 holders.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2021 was Morgan Stanley, an estimated $57.6K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2021 was Armistice Capital, an estimated $1.45M sold.

Based on aggregated 13F filings for Q4 2021.